Embracing Communities of Innovation: Massachusetts Our strategy to transform patients’ lives has always centered on building state-of-the-art research centers within communities that spark innovation. Massachusetts stands as a global hub…
Cytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the eighth annual Cytokinetics Communications Grant Program.…
Layoff Tracker: Rome Trims Already-Small Team Amid Strategic Review 2024 was a tough year for the biopharma industry, with several companies including Bayer, Bristol Myers Squibb and Johnson & Johnson…
Employee-led initiative supports global partnerships to build stronger, climate-resilient health systems Takeda (TSE:4502/NYSE:TAK) today committed JPY 4.6 billion (approx. USD 32.1 million) to four new Global Corporate Social Responsibility (CSR)…
Silent global health crisis threatens lives, driving heart disease, stroke, and kidney failure worldwide The World Health Organization (WHO) today released its second Global hypertension report, showing that 1.4 billion people…
WuXi Biologics Selected as Constituent of FTSE4Good Index Series for Fifth Consecutive Year WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has…
Potential First Approved Treatment in the EU Targeting NF1-Associated Plexiform Neurofibromas koselugo (selumetinib), an oral, selective MEK inhibitor, has been recommended for approval in the European Union (EU) for the treatment…
CHMP Recommends EU Approval of Tezspire for Chronic Rhinosinusitis with Nasal Polyps AstraZeneca and Amgen’s Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for the treatment of adult…
First Parkinson’s disease patient treated in BlueRock’s pivotal Phase III trial of investigational cell therapy bemdaneprocel BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned, independently operated subsidiary…
Pharma Giant Expands Into Emerging Psychedelic Therapies With AbbVie’s $1.2 billion acquisition of Gilgamesh Pharmaceuticals’ lead depression drug, the psychedelic therapeutics space has soundly rebounded from Lykos’ rejection last year.…
Critics Warn Plan May Hinder Innovation and Patient Access The FDA’s proposed Rare Disease Evidence Principles review process is a starting point for getting rare disease therapies across the finish…
The fight against misinformation goes to the heart of trust in public health We are at a critical juncture. While best estimates conclude that vaccines have saved more than 150…